Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arena Pharmaceuticals, Inc. - Common Stock (NQ:ARNA)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Mar 10, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Arena Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 Next >
Arena Pharmaceuticals Inc. (ARNA) Climbs to Annual-High Share Price
Via Investor Brand Network
Arena Pharmaceuticals Inc. (ARNA) Climbs to Annual-High Share Price
Via Investor Brand Network
Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates
From Arena Pharmaceuticals, Inc.
Via Business Wire
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Arena Pharmaceuticals, Inc.
Via Business Wire
Arena Pharmaceuticals to Release Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update on February 23
From Arena Pharmaceuticals, Inc.
Via Business Wire
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Arena Pharmaceuticals, Inc.
Via Business Wire
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Arena Pharmaceuticals, Inc.
Via Business Wire
Arena Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Arena Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ARNA
From Halper Sadeh LLP
Via Business Wire
Pfizer to Acquire Arena Pharmaceuticals
From Pfizer Inc.
Via Business Wire
Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod CULTIVATE Study A
From Arena Pharmaceuticals, Inc.
Via Business Wire
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Arena Pharmaceuticals, Inc.
Via Business Wire
Arena Reports Third Quarter Financial Results and Key Program Updates
From Arena Pharmaceuticals, Inc.
Via Business Wire
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Arena Pharmaceuticals, Inc.
Via Business Wire
Arena Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Corporate Update on November 4
From Arena Pharmaceuticals, Inc.
Via Business Wire
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Arena Pharmaceuticals, Inc.
Via Business Wire
Arena Pharmaceuticals to Host Virtual R&D Investor Calls and Participate in Upcoming September Investor Conferences
From Arena Pharmaceuticals, Inc.
Via Business Wire
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Arena Pharmaceuticals, Inc.
Via Business Wire
Arena Reports Second Quarter Financial Results and Key Program Updates
From Arena Pharmaceuticals, Inc.
Via Business Wire
Arena Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Corporate Update on August 5
From Arena Pharmaceuticals, Inc.
Via Business Wire
Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment of Serious Immune-Mediated Inflammatory Diseases
From Arena Pharmaceuticals, Inc.
Via Business Wire
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Arena Pharmaceuticals, Inc.
Via Business Wire
Arena Pharmaceuticals Appoints Doug Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development
From Arena Pharmaceuticals, Inc.
Via Business Wire
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Arena Pharmaceuticals, Inc.
Via Business Wire
Steven Schoch Elected to Arena Pharmaceuticals Board of Directors
From Arena Pharmaceuticals, Inc.
Via Business Wire
Arena Pharmaceuticals Announces Orphan Drug Designation for Etrasimod for the Treatment of Eosinophilic Esophagitis (EoE)
From Arena Pharmaceuticals, Inc.
Via Business Wire
Rapid Development of Cannabinoid Based Medicinal Products Reaching New Levels
Via FinancialNewsMedia
Topics Cannabis Economy
Arena Pharmaceuticals Announces First Participant Randomized in Phase 2 Trial Evaluating Temanogrel in Coronary Microvascular Obstruction (cMVO)
From Arena Pharmaceuticals, Inc.
Via Business Wire
Arena Pharmaceuticals Earns "A" Rating from MSCI ESG, a Leading Rating Agency for Sustainable Investments
From Arena Pharmaceuticals, Inc.
Via Business Wire
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Arena Pharmaceuticals, Inc.
Via Business Wire
Arena Pharmaceuticals Earns Prime Status from ISS ESG, a Leading Rating Agency for Sustainable Investments
From Arena Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.